ENORMOUS THANKS to our Conference Sponsors / PWS medication trial innovators

Tomorrow, Latham Centers will co-host the 2nd Annual Prader-Willi Syndrome Conference entitled “A Bright Future.” The Mac Pact and Latham Centers would like to extend our deep appreciation to our Conference Sponsors, Levo Therapeutics, Millendo Therapeutics, and Soleno Therapeutics, who help make conferences like these possible, giving people in the PWS community an opportunity to meet and learn from one another. All three sponsors will be represented at the conference tomorrow (Saturday, June 1st). Profiles of each company follow:

Levo Therapeutics

Levo Therapeutics is a biotechnology company dedicated to using genetic insights to advance treatments for Prader-Willi syndrome and related disorders. To learn more about Levo, please visit www.levotx.com.

CARE-PWS is a clinical study evaluating an investigational medicine for the treatment of Prader-Willi syndrome (PWS) in 7-18 year olds. People with PWS have a constant feeling of hunger, known as hyperphagia.

To learn more about the Trial, contact Levo at: contactus@levotx.com.

Millendo Therapeutics, Inc.

Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit www.millendo.com.

To learn more about the Trial, contact Alisha Sternenberger, Head of Patient Engagement: Sternenberger@millendo.com

Soleno Therapeutics

Soleno Therapeutics, Inc. is committed to developing safe and effective therapeutic products that improve the lives of patients living with complex, life-threatening rare diseases with unmet medical needs. They are focused on the development of DCCR for the treatment of Prader-Willi syndrome (PWS). DCCR is currently being evaluated in the DESTINY-PWS phase III trial. There are 15 active clinical sites for the study across the United States, and more sites will be opened over the next month. Please visit clinicaltrials.gov and enter identifier NCT03440814 to learn more about the study. If positive, the data from this study will be used to support approval of DCCR for use in patients with PWS. https://soleno.life/

To learn more about the Trial, contact Neil Cowan, Senior VP for Drug Development: neil@soleno.life

Forget to sign up for PWS: A Bright Future https://pwsabrightfuture.eventbrite.com? As of today, we have a few spaces available for last-minute registrations. Please email kfryklund@lathamcenters.org if you’d like to register on-site tomorrow morning, June 1st.


Subscribe to Our Newsletter